MRK logo Merck & Co. +
Merck & Co.
+

Merck & Co. (MRK) Business News

Track Merck & Co. in real time with a live news feed covering Merck & Co. stock news, official press releases, company announcements, and an archive of historical Merck & Co. news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
12:35 PM | Tuesday | Jun 30, 2026 Proactive Investors

Merck, AbbVie probed by US lawmakers over China clinical trials: report

News Thumbnail
9:08 AM | Tuesday | Jun 30, 2026 Schaeffers Research

Stock Futures Quiet to End the Month, Quarter

News Thumbnail
8:19 AM | Tuesday | Jun 30, 2026 Proactive Investors - Finance

Merck, AbbVie probed by US lawmakers over China clinical trials: report

News Thumbnail
7:45 AM | Tuesday | Jun 30, 2026 Fool - Investing News

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

News Thumbnail
12:35 PM | Tuesday | Jun 30, 2026 Proactive Investors

Merck, AbbVie probed by US lawmakers over China clinical trials: report

News Thumbnail
9:08 AM | Tuesday | Jun 30, 2026 Schaeffers Research

Stock Futures Quiet to End the Month, Quarter

News Thumbnail
7:45 AM | Tuesday | Jun 30, 2026 Fool - Investing News

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

News Thumbnail
10:31 AM | Monday | Jun 29, 2026 Zacks Investment Research

Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?

News Thumbnail
6:45 AM | Monday | Jun 29, 2026 Business Wire

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

News Thumbnail
10:01 AM | Friday | Jun 26, 2026 Zacks Investment Research

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

News Thumbnail
7:32 AM | Friday | Jun 26, 2026 Benzinga

Qualcomm, Merck, Rockwell Automation And A Real Estate Stock On CNBC's ‘Final Trades'

News Thumbnail
11:06 AM | Thursday | Jun 25, 2026 Zacks Investment Research

MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer

News Thumbnail
6:45 AM | Thursday | Jun 25, 2026 Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

News Thumbnail
12:25 PM | Wednesday | Jun 24, 2026 Zacks Investment Research

Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC

News Thumbnail

Merck, AbbVie probed by US lawmakers over China clinical trials: report

Proactive Investors

12:35 PM | Tuesday | Jun 30, 2026

news photo
Loading...

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.

Read full article redirect
12:35 PM | Tuesday | Jun 30, 2026

Merck, AbbVie probed by US lawmakers over China clinical trials: report

Proactive Investors

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.

Read full article arrow
News Thumbnail
9:08 AM | Tuesday | Jun 30, 2026

Stock Futures Quiet to End the Month, Quarter

Schaeffers Research

Stock futures are pointed lower to end the month and quarter as AI capex concerns linger

Read full article arrow
News Thumbnail
8:19 AM | Tuesday | Jun 30, 2026

Merck, AbbVie probed by US lawmakers over China clinical trials: report

Proactive Investors - Finance

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...

Read full article arrow
News Thumbnail
7:45 AM | Tuesday | Jun 30, 2026

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Fool - Investing News

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Read full article arrow
News Thumbnail
12:35 PM | Tuesday | Jun 30, 2026

Merck, AbbVie probed by US lawmakers over China clinical trials: report

Proactive Investors

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.

Read full article arrow
News Thumbnail
9:08 AM | Tuesday | Jun 30, 2026

Stock Futures Quiet to End the Month, Quarter

Schaeffers Research

Stock futures are pointed lower to end the month and quarter as AI capex concerns linger

Read full article arrow
News Thumbnail
7:45 AM | Tuesday | Jun 30, 2026

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Fool - Investing News

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Read full article arrow
News Thumbnail
10:31 AM | Monday | Jun 29, 2026

Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?

Zacks Investment Research

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read full article arrow
News Thumbnail
6:45 AM | Monday | Jun 29, 2026

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.

Read full article arrow
News Thumbnail
10:01 AM | Friday | Jun 26, 2026

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Read full article arrow
News Thumbnail
7:32 AM | Friday | Jun 26, 2026

Qualcomm, Merck, Rockwell Automation And A Real Estate Stock On CNBC's ‘Final Trades'

Benzinga

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, named Qualcomm Incorporated (NASDAQ:QCOM) as his final trade.

Read full article arrow
News Thumbnail
11:06 AM | Thursday | Jun 25, 2026

MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer

Zacks Investment Research

Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Read full article arrow
News Thumbnail
6:45 AM | Thursday | Jun 25, 2026

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead's Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative.

Read full article arrow
News Thumbnail
12:25 PM | Wednesday | Jun 24, 2026

Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC

Zacks Investment Research

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

Read full article arrow
News Thumbnail